$RCKT March 28 PDUFA: Regulatory Setup Looks Better Than Pricing Implies

$RCKT Started a nice position here after spending time on the regulatory and clinical submission. This is high-risk biotech, but the approval odds look significantly better than what the current market price implies. I didn’t approach this as a simple PDUFA trade. I went through the regulatory framework and clinical package, (I am not a regulatory professional on drug submissions, but I am one on medical device and biotech -more genomics- submissions, so I understand FDA process ) and the setup is stronger than I initially expected. Breaking it down by importance. Regulatory framework is the most important factor here. This is an ultra-rare pediatric disease with no approved curative options, which is exactly the type of indication where the FDA applies the most flexibility. The agency has a clear track record of supporting gene therapies in rare pediatric settings when there is meaningful benefit. Single-arm data is acceptable for this indication because the natural history is well understood and randomized trials are not practical or ethical. The regulatory bar is intentionally lower for diseases like this. On the clinical side, the data shows durable efficacy with real functional improvement, not just biomarker movement. Survival outcomes significantly exceed what is expected based on natural history, which is one of the strongest aspects of the package. The safety profile is consistent with other approved AAV gene therapies, with no unexpected signals. There is nothing in the data that obviously points to elevated CRL risk due to efficacy or safety. From a setup and risk-reward perspective, the PDUFA date is set with no major review delays or public red flags. Orphan and RMAT designations exist specifically to accelerate approvals in cases like this and meaningfully improve the probability of approval. This is a binary event, but the downside is known and the upside is asymmetric, making the probability-weighted outcome attractive. Certainly this is not a slam dunk and it is absolutely high-risk biotech. That said, after reviewing the submission, this looks like a situation where approval odds may be higher than the stock price suggests. So taking a position going into PDUFA, the risk-reward looks compelling. Not investment advice. Biotech is volatile. Use discretionary capital only